AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...
On supercomputers and life sciences, listening to Treasury naysayers risks letting work and political capital slip away ...
CORE EARNINGS PER SHARE: Core earnings per share are expected to rise to $2.07 from $1.45 the year prior, according to the same consensus. AstraZeneca's stock is up 7.9% since the start of 2024.
AstraZeneca has cancelled a multi-million pound investment in a vaccine plant in Merseyside because the government failed to ...
The pharmaceutical giant announced its decision to cancel its planned investment just two days after Chancellor Rachel Reeves ...
Sir Chris Bryant said the Government made a "significant offer" to AstraZeneca but still stopped short of the £90m offered by ...
The pharmaceutical giant claimed the Labour Government failed to match its predecessor’s offer of help for the Merseyside ...
A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...
Metro Mayor Steve Rotheram has said he is hoping to restart talks with AstraZeneca after it scrapped plans to invest £450m in ...
There can be no greater example of Labour's naive attitude to growth and business than its refusal to back an investment on Merseyside by British pharmaceutical pioneer AstraZeneca.
Telegraph investigation finds ‘critical’ information missing from early warnings about AstraZeneca vaccine’s side effects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback